Literature DB >> 9600956

Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells.

J Gong1, D Chen, M Kashiwaba, Y Li, L Chen, H Takeuchi, H Qu, G J Rowse, S J Gendler, D Kufe.   

Abstract

Immunological unresponsiveness established by the elimination or anergy of self-reactive lymphocyte clones is of importance to immunization against tumor-associated antigens. In this study, we have investigated induction of immunity against the human MUC1 carcinoma-associated antigen in MUC1 transgenic mice unresponsive to MUC1 antigen. Immunization of adult MUC1 transgenic mice with irradiated MUC1-positive tumor cells was unsuccessful in reversing unresponsiveness to MUC1. By contrast, fusions of dendritic cells with MUC1-positive tumor cells induced cellular and humoral immunity against MUC1. Immunization with the dendritic cell fusions that express MUC1 resulted in the rejection of established metastases and no apparent autoimmunity against normal tissues. These findings demonstrate that unresponsiveness to the MUC1 tumor-associated antigen is reversible by immunization with heterokaryons of dendritic cells and MUC1-positive carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9600956      PMCID: PMC27657          DOI: 10.1073/pnas.95.11.6279

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

Review 1.  The dendritic cell system and its role in immunogenicity.

Authors:  R M Steinman
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

2.  Generation of antigen-specific CD8+ CTLs from naive precursors.

Authors:  A Mehta-Damani; S Markowicz; E G Engleman
Journal:  J Immunol       Date:  1994-08-01       Impact factor: 5.422

3.  Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line.

Authors:  S R Hull; A Bright; K L Carraway; M Abe; D F Hayes; D W Kufe
Journal:  Cancer Commun       Date:  1989

4.  Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen.

Authors:  L Perey; D F Hayes; P Maimonis; M Abe; C O'Hara; D W Kufe
Journal:  Cancer Res       Date:  1992-05-01       Impact factor: 12.701

5.  Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo.

Authors:  V Flamand; T Sornasse; K Thielemans; C Demanet; M Bakkus; H Bazin; F Tielemans; O Leo; J Urbain; M Moser
Journal:  Eur J Immunol       Date:  1994-03       Impact factor: 5.532

6.  Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro.

Authors:  A B Bakker; G Marland; A J de Boer; R J Huijbens; E H Danen; G J Adema; C G Figdor
Journal:  Cancer Res       Date:  1995-11-15       Impact factor: 12.701

7.  Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity.

Authors:  J I Mayordomo; T Zorina; W J Storkus; L Zitvogel; C Celluzzi; L D Falo; C J Melief; S T Ildstad; W M Kast; A B Deleo
Journal:  Nat Med       Date:  1995-12       Impact factor: 53.440

8.  Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes.

Authors:  A Porgador; E Gilboa
Journal:  J Exp Med       Date:  1995-07-01       Impact factor: 14.307

9.  Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ.

Authors:  K Inaba; J P Metlay; M T Crowley; R M Steinman
Journal:  J Exp Med       Date:  1990-08-01       Impact factor: 14.307

10.  Antigen acquisition by dendritic cells: intestinal dendritic cells acquire antigen administered orally and can prime naive T cells in vivo.

Authors:  L M Liu; G G MacPherson
Journal:  J Exp Med       Date:  1993-05-01       Impact factor: 14.307

View more
  44 in total

1.  Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery.

Authors:  W Asavaroengchai; Y Kotera; J J Mulé
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-15       Impact factor: 11.205

Review 2.  Dendritic cells: immune saviors or Achilles' heel?

Authors:  C W Cutler; R Jotwani; B Pulendran
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

3.  Towards immunotherapy of pancreatic cancer.

Authors:  I F McKenzie; V Apostolopoulos
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

4.  Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.

Authors:  Jacalyn Rosenblatt; Baldev Vasir; Lynne Uhl; Simona Blotta; Claire Macnamara; Poorvi Somaiya; Zekui Wu; Robin Joyce; James D Levine; Dilani Dombagoda; Yan Emily Yuan; Karen Francoeur; Donna Fitzgerald; Paul Richardson; Edie Weller; Kenneth Anderson; Donald Kufe; Nikhil Munshi; David Avigan
Journal:  Blood       Date:  2010-10-28       Impact factor: 22.113

5.  Dendritic cells, pulsed with lysate of allogeneic tumor cells, are capable of stimulating MHC-restricted antigen-specific antitumor T cells.

Authors:  Reza Mahdian; Parviz Kokhaei; Hossein Motieian Najar; Katja Derkow; Aniruddha Choudhury; Håkan Mellstedt
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 6.  CD4 T cells in tumor immunity.

Authors:  Mara Gerloni; Maurizio Zanetti
Journal:  Springer Semin Immunopathol       Date:  2005-03-15

7.  Immunotherapy of tumor with vaccine based on basic fibroblast growth factor-activated fibroblasts.

Authors:  Xiuying Li; Yongsheng Wang; Yuwei Zhao; Hengxiu Yang; Aiping Tong; Chengjian Zhao; Huashan Shi; Yang Li; Zhenlin Wang; Yuquan Wei
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-10       Impact factor: 4.553

Review 8.  Novel immunotherapies.

Authors:  Qing Yi
Journal:  Cancer J       Date:  2009 Nov-Dec       Impact factor: 3.360

9.  Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1.

Authors:  Chuanlin Ding; Li Wang; Jose Marroquin; Jun Yan
Journal:  Blood       Date:  2008-07-31       Impact factor: 22.113

10.  Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells.

Authors:  Baldev Vasir; Zekui Wu; Keith Crawford; Jacalyn Rosenblatt; Corrine Zarwan; Adam Bissonnette; Donald Kufe; David Avigan
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.